Bangkok Genomics Innovation PCL (BKK:BKGI)

BKK:BKGI Income Statement

Financials in millions THB. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Revenue	333.02	337.59	245.39	304.77
Revenue Growth (YoY)	12.36%	37.57%	-19.48%	-
Cost of Revenue	198.02	197.52	129.29	147.26
Gross Profit	134.99	140.08	116.1	157.52
Selling, General & Admin	105.94	94.5	85.22	93.97
Other Operating Expenses	-7.02	-8.27	-1.95	-15.29
Operating Expenses	100.84	87.61	82.52	77.78
Operating Income	34.15	52.46	33.58	79.73
Interest Expense	-1.42	-1.36	-1.64	-1.07
Earnings From Equity Investments	-0.4	-0.08	-	-
Pretax Income	32.33	51.02	31.94	78.66
Income Tax Expense	0.71	0.86	-0.2	3.54
Earnings From Continuing Operations	31.62	50.16	32.14	75.11
Minority Interest in Earnings	0.04	0.01	-	-
Net Income	31.65	50.17	32.14	75.11
Net Income to Common	31.65	50.17	32.14	75.11
Net Income Growth	-28.85%	56.09%	-57.21%	-
Shares Outstanding (Basic)	600	567	440	214
Shares Outstanding (Diluted)	600	567	440	214
Shares Change (YoY)	13.83%	28.91%	105.72%	-
EPS (Basic)	0.05	0.09	0.07	0.35
EPS (Diluted)	0.05	0.09	0.07	0.35
EPS Growth	-37.50%	21.09%	-79.20%	-
Free Cash Flow	-11.86	-23.46	67.03	53.9
Free Cash Flow Per Share	-0.02	-0.04	0.15	0.25
Dividend Per Share	0.050	0.050	0.054	4.666
Dividend Growth	-	-8.26%	-98.83%	-
Gross Margin	40.54%	41.49%	47.31%	51.68%
Operating Margin	10.26%	15.54%	13.69%	26.16%
Profit Margin	9.50%	14.86%	13.10%	24.64%
Free Cash Flow Margin	-3.56%	-6.95%	27.31%	17.68%
EBITDA	49.44	64.83	44.16	88.82
EBITDA Margin	14.85%	19.20%	18.00%	29.14%
D&A For EBITDA	15.29	12.37	10.57	9.08
EBIT	34.15	52.46	33.58	79.73
EBIT Margin	10.26%	15.54%	13.69%	26.16%
Effective Tax Rate	2.19%	1.69%	-	4.51%
Revenue as Reported	333.02	337.59	245.39	304.77

Source: S&P Global Market Intelligence. Standard template. Financial Sources.